Found 2528 clinical trials
Moxidectin for LF Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- 0 views
- 16 Feb, 2024
- 1 location
Hyperimmune Plasma in Patients With COVID-19 Severe Infection
Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma or "hyperimmune" plasma was one of the most widespread and effective anti-infective treatments in the pre-antibiotic era and one of the founding pillars of immunology, and has also been used during the SARS (2002-2003) and Ebola (2014-2016) viral epidemy …
- 0 views
- 16 Feb, 2024
- 6 locations
Performance of CAD/CAM Milled and 3D-printed Full-arch Implant-supported Provisionals Restorations
This clinical trial aims to compare the performance of CAD/CAM-milled and 3D-printed full-arch implant-supported provisional restorations in patients at the Advanced Implant Prosthetics Clinic of the Complutense University of Madrid, of both sexes, over 18 years of age, edentulous upper, lower or both, whose treatment plan is at least a …
- 0 views
- 02 Mar, 2026
- 1 location
The Influence of a Perturbation Training on Balance Recovery of Old Adults: a Randomized Controlled Trial
Falls are major contributors for immobility and independency. Most falls in older adults occur during walking after a sudden unexpected loss of balance. It was well-established that balance can be improved by performance of a training program that provides perturbation (unexpected perturbations of balance). The main aim of the current …
- 0 views
- 16 Feb, 2024
- 3 locations
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
The primary objective of the study is to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study
- 0 views
- 05 Aug, 2020
Increasing African Immigrant Women's Participation in Breast Cancer Screening
New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low …
- 0 views
- 05 Aug, 2020
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
Evaluation of the efficacy and safety of NTX in adult patients (18 years and <60 years), with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm. 135 patients will be randomized to either Nitazoxanide (n=90) or placebo (n=45) (2:1). Simple blind design. Primary endpoint: eradication of …
- 0 views
- 05 Aug, 2020
Breastfeeding Education Given to Primiparous Mothers With the Teach-Back Method
The Teach-Back method was initially developed as a communication technique for patients to remember important information about their diagnosis, treatment or medication and to understand what to do. Method; It requires recalling and explaining any information learned during the interaction between the healthcare team and clients. It has been seen …
- 0 views
- 18 Jan, 2024
- 1 location
Upper Limb Loss Perturbation Response
Recent investigations have suggested that persons with upper limb loss experience a high prevalence of falls with a quarter of reported falls resulting from a trip. Moreover, studies indicate that missing part of an arm may negatively impact balance and that use of a prosthesis exacerbates this problem. While the …
- 0 views
- 16 Feb, 2024
- 1 location
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 16 Feb, 2024
- 4 locations